NASDAQ:CAMP
Camp4 Therapeutics Corp
Camp4 Therapeutics Corp's revenue grew 436.5% in fiscal 2025 to $3.5M while operating margin rose to −1502.4%, its highest in 3 years. Free cash flow was −$29.8M, −852.8% of revenue, and the diluted share count rose 547.8%.Summary generated from Camp4 Therapeutics Corp's SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$3.5M
Revenue growth+436.5%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−1502.4%
Net margin−2298.5%
ROICn/a
Return on equity−145.1%
Debt / equityn/a
Free cash flow−$29.8M
FCF margin−852.8%
Share count change+547.8%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 0 | 1 | 3 |
| Operating income | −52 | −53 | −53 |
| Net income | −49 | −52 | −80 |
| Free cash flow | −45 | −46 | −30 |
Recent filings
- 8-KRegulation FD disclosure
Sep 28, 2026 - 4Insider transaction report
Sep 2, 2026 - 4Insider transaction report
Aug 31, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KEntry into a material agreement
Aug 4, 2026 - 8-KRegulation FD disclosure
Jul 27, 2026 - 8-KDirector or officer change
Jun 12, 2026